BCL2 and cancer: The enhanced motility of non-small cell lung cancer (NSCLC) cells and cancer aggressiveness was linked to increased TFEB expression [20], which promotes cancer cell proliferation and/or the induction of anti-apoptotic genes, such as BCL2 and BIRC7 in melanoma [21], or fuels cell metabolism and supports tumor progression in pancreatic cancer [22].